Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curatis Holding AGXSWX:CURN -4.67%33 3-Year EBITDA Growth Rate is 90.30% as of Dec. 2025, which is 56% above its 10-year median of 57.95. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 7 warning signs investors should review. Among 813 Drug Manufacturers companies, Curatis Holding AG ranks better than 97.05% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 90.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Curatis Holding AG was 90.30% per year. The lowest was 25.60% per year. And the median was 57.95% per year.
Curatis Holding AG (XSWX:CURN) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Curatis Holding AG 3-Year EBITDA Growth Rate Related Terms
XSWX:CURN vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's 3-Year EBITDA Growth Rate falls into.
Curatis Holding AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 90.30% mean?
Curatis Holding AG (XSWX:CURN) has a 3-Year EBITDA Growth Rate of 90.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Curatis Holding AG and its competitors. This is 56% above median its historical median of 57.95. Over the past decade, Curatis Holding AG's 3-Year EBITDA Growth Rate has ranged from 25.60 to 90.30. According to the industry distribution chart, Curatis Holding AG ranks #24 out of 813 companies in the Drug Manufacturers industry, placing it in the top 3%.
Is Curatis Holding AG's 3-Year EBITDA Growth Rate too high?
Curatis Holding AG's current 3-Year EBITDA Growth Rate of 90.30% is 56% above median its 10-year median of 57.95. Over the past 10 years, this metric has ranged from a low of 25.60 to a high of 90.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Curatis Holding AG's value of 90.30% is 914.6% above this industry median. Based on the distribution chart, Curatis Holding AG ranks #24 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #24 out of 813 companies for 3-Year EBITDA Growth Rate. This places Curatis Holding AG in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Curatis Holding AG's value of 90.30% is 914.6% above this benchmark. Historically, Curatis Holding AG's own 3-Year EBITDA Growth Rate has ranged from 25.60 to 90.30 over the past decade. While the company's 10-year median is 57.95 vs. the industry median of 8.90, Curatis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curatis Holding AG's current 3-Year EBITDA Growth Rate of 90.30% is 914.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Curatis Holding AG and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current 3-Year EBITDA Growth Rate is 90.30%, which is 56% above median its own 10-year median of 57.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current 3-Year EBITDA Growth Rate of 90.30%. The current 3-Year EBITDA Growth Rate is 90.30%, which is 56% above median its 10-year median of 57.95 and 914.6% above the Drug Manufacturers industry median of 8.90. Curatis Holding AG's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current 3-Year EBITDA Growth Rate is 90.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score
Get the complete analysis for XSWX:CURN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
